Article
Gastroenterology & Hepatology
Chikako Watanabe, Masakazu Nagahori, Toshimitsu Fujii, Kaoru Yokoyama, Naoki Yoshimura, Taku Kobayashi, Hirokazu Yamagami, Kazuya Kitamura, Kagaya Takashi, Shiro Nakamura, Makoto Naganuma, Shunji Ishihara, Motohiro Esaki, Maria Yonezawa, Reiko Kunisaki, Atsushi Sakuraba, Naoaki Kuji, Soichiro Miura, Toshifumi Hibi, Yasuo Suzuki, Ryota Hokari
Summary: This study found that non-adherence to mesalamine was underestimated by physicians in pregnant UC patients, leading to disease relapse and potentially adverse pregnancy outcomes. Non-adherence was identified as an independent risk factor for relapse and could impact pregnancy outcomes. Preconceptional education on medication safety and avoiding self-discontinuation is necessary for these patients.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Review
Gastroenterology & Hepatology
Nicholas E. Burr, David J. Gracie, Christopher J. Black, Alexander C. Ford
Summary: In a network meta-analysis, upadacitinib 45 mg once daily ranked first for clinical remission in all patients, patients naive to anti-TNF-alpha drugs and patients previously exposed. Infliximab 10 mg/kg ranked first for endoscopic improvement. Most drugs were safe and well tolerated.
Article
Pharmacology & Pharmacy
Liang Dai, Yingjue Tang, Wenjun Zhou, Yanqi Dang, Qiaoli Sun, Zhipeng Tang, Mingzhe Zhu, Guang Ji
Summary: Mesalamine treatment partially restored the disrupted gut microbiota diversity and community composition in ulcerative colitis (UC) patients. Many genera and metabolites were significantly altered in UC group and reversed by mesalamine, indicating its beneficial role in modulating gut microbiota signature with correlated metabolites in different pathways as potential therapeutic targets and biomarkers for UC.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Amandeep Singh, Uttam Kumar Mandal, Raj Kumar Narang
Summary: The study aimed to develop enteric-coated pectin pellets containing mesalamine and S.bulardii for specific colon targeted drug delivery for ulcerative colitis management. Experimental results demonstrated the potential of the coated pellet formulation for effective drug delivery and improved therapeutic effects.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2021)
Article
Gastroenterology & Hepatology
Shomron Ben-Horin, Ofir Har-Noy, Konstantinos H. Katsanos, Xavier Roblin, Minhu Chen, Xiang Gao, Doron Schwartz, Jae Hee Cheon, Monica Cesarini, Daniela Bojic, Marijana Protic, Angeliki Theodoropoulou, Heba Abu-Kaf, Tal Engel, Jian Tang, Pauline Veyrard, Xiaoqing Lin, Ren Mao, Dimitrios Christodoulou, Konstantinos Karmiris, Tamara Knezevic-Ivanovski
Summary: In this randomized controlled trial, the combination of mesalamine with corticosteroids did not show superior efficacy compared to corticosteroids alone in hospitalized patients with acute severe ulcerative colitis (ASUC). However, there was a potential indication that the need for biologics was reduced in the mesalamine group within 90 days.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Medicine, General & Internal
G. N. Devamsh, Mallikarjun Patil, Syed Shafiq
Summary: A 45-year-old woman presented with bloody diarrhoea and significant weight loss. She was diagnosed with acute ulcerative colitis and started on prednisolone and mesalamine therapy. However, within 24 hours, she developed symptoms of dizziness and chest discomfort, and an ECG revealed sinus bradycardia. After stopping mesalamine, her heart rate returned to normal and she remained symptom-free. This is a rare case of mesalamine-induced severe symptomatic sinus bradycardia, with only four reported cases in the literature.
Article
Gastroenterology & Hepatology
Chu K. Yao, Rebecca E. Burgell, Kirstin M. Taylor, Mark G. Ward, Antony B. Friedman, Jacqueline S. Barrett, Jane G. Muir, Peter R. Gibson
Summary: Limited data are available on the effects of fermentable fiber intake on altering intestinal pH and transit in UC patients. This study found that increasing fermentable fiber intake lowered overall and distal pH in healthy controls, and only decreased cecal pH in UC patients. Colonic transit in UC patients varied widely after low-fiber intake but tended to normalize after high fermentable fiber intake. Hypothetical coating dissolution profiles were heterogeneous in UC patients.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Review
Gastroenterology & Hepatology
Akshita Gupta, Amy Yu, Laurent Peyrin-Biroulet, Ashwin N. Ananthakrishnan
Summary: In patients with UC in endoscopic remission, persistent histologic activity is associated with higher rates of relapse. Greater degree of normalization may have a stronger impact. Individual histologic features such as basal plasmacytosis, neutrophilic infiltrations, mucin depletion, and crypt architectural irregularities predicted relapse.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Medicine, General & Internal
Rahma Elmahdi, Camilla E. Lemser, Sandra B. Thomsen, Kristine H. Allin, Manasi Agrawal, Tine Jess
Summary: This meta-analysis revealed that patients with pediatric-onset IBD have a more than 2-fold increased rate of cancer compared to the general pediatric population, primarily due to an increased rate of gastrointestinal cancers.
Article
Gastroenterology & Hepatology
Christopher Ma, Jenny Jeyarajah, Leonardo Guizzetti, Claire E. Parker, Siddharth Singh, Parambir S. Dulai, Geert R. D'Haens, William J. Sandborn, Brian G. Feagan, Vipul Jairath
Summary: This study developed and validated a clinical decision support tool to discriminate patients with mild-to-moderate UC treated with mesalamine who have achieved endoscopic improvement. The tool showed good discriminative performance in identifying endoscopic improvement in these patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Gastroenterology & Hepatology
Nick Dai, Omar Haidar, Alan Askari, Jonathan P. Segal
Summary: This study aimed to understand the changing prevalence of colectomy in Ulcerative Colitis (UC) over time. The results showed that the overall colectomy rate has decreased over the past three decades. Biologics may have played a role in reducing the risk of colectomy, but the relative risk reduction is likely to be modest.
DIGESTIVE AND LIVER DISEASE
(2023)
Review
Plant Sciences
Peng-De Lu, Meng-Chen Yuan, Xing-Ping Quan, Jin-Fen Chen, Yong-Hua Zhao
Summary: This study investigates the multiple efficacies of licorice on ulcerative colitis (UC) through systematic review, meta-analysis, and network pharmacology. The results show that licorice extract and its active compounds have significant therapeutic effects on UC, including reducing colitis severity, improving colonic shortness, and decreasing inflammation-related factors. The network pharmacology results indicate that the therapeutic mechanisms of licorice mainly involve anti-inflammation, anti-oxidative stress, immunomodulation, and microbiota homeostasis.
JOURNAL OF ETHNOPHARMACOLOGY
(2022)
Review
Gastroenterology & Hepatology
Anouk M. Wijnands, Michiel E. de Jong, Maurice W. M. D. Lutgens, Frank Hoentjen, Sjoerd G. Elias, Bas Oldenburg
Summary: A systematic review and meta-analysis identified 13 risk factors and 5 protective factors for advanced colorectal neoplasia in IBD patients. These findings could contribute to an improved surveillance based on CRC risk stratification in IBD.
Review
Gastroenterology & Hepatology
Yakup Kilic, Shahed Kamal, Farah Jaffar, Danujan Sriranganathan, Mohammed Nabil Quraishi, Jonathan P. Segal
Summary: Inflammatory bowel disease (IBD) is a multisystem disease that affects various body systems. The extraintestinal manifestations of IBD are frequent and impact the morbidity and mortality of patients with UC and CD.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Medicine, General & Internal
Yafei Qin, Grace Wang, Dejun Kong, Guangming Li, Hongda Wang, Hong Qin, Hao Wang
Summary: CMV reactivation in patients with ulcerative colitis (UC) is significantly associated with disease severity, pancolitis, older age of UC onset, and the use of glucocorticoids, immunosuppressants, and azathioprine. However, infliximab treatment does not increase the risk of CMV reactivation, while 5-aminosalicylic acid is linked to a lower risk. Monitoring for these risk factors is crucial for timely diagnosis and treatment in UC patients.